Background: Chronic obstructive pulmonary disease (COPD) is a major public health concern, accounting for 3 million deaths annually, 90% of which occur in low- and middle-income countries. Pulmonary tuberculosis (PTB) as a contributory factor in the aetiology of COPD is under debate, with most epidemiologic evidence suggesting a positive association. Objectives: To compile a systematic review of evidence for an association between PTB and the development of chronic airflow obstruction (CAO). Methods: We performed a systematic review of original English-language, peer-reviewed literature using the PubMed/MEDLINE database. CAO was defined by spirometry [FEV1:FVC ratio <0.70 or <LLN (lower limit of normal) for age]. Results: Nineteen studies (1 case series, 3 case-control studies, 4 cohort studies, 8 single-centre cross-sectional studies and 3 multi-centre cross-sectional studies) met the eligibility criteria. All but 2 reported a positive association between PTB and CAO. Three of 4 large population-based surveys (n = 4,291-8,066) confirmed a significant association between PTB and CAO (OR 1.37 - 2.94). A formal meta-analysis was not possible owing to marked heterogeneity between studies. Conclusions: This systematic review confirms evidence for a positive association between a past history of tuberculosis and the presence of CAO. The association is independent of cigarette smoking. Causality is likely but cannot be assumed.

Keywords:
Tuberculosis, Chronic obstructive pulmonary disease, Airflow obstruction
1.
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-2128.
2.
WHO: Burden of Chronic Obstructive Pulmonary Disease. http://www.who.int/respiratory/copd/burden/en/index.html (accessed August 29, 2011).
3.
Global Initiative for Chronic Obstructive Lung Disease: global strategy for the diagnosis, management, and prevention of COPD. http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html (accessed March 4, 2013).
4.
Salvi SS, Barnes PJ: Chronic obstructive pulmonary disease in non-smokers. Lancet 2009;374:733-743.
5.
Baig IM, Saeed W, Khalil KF: Post-tuberculous chronic obstructive pulmonary disease. J Coll Physicians Surg Pak 2010;20:542-544.
6.
Chan-Yeung M, Ho A, Cheung A, Liu R, Yee W, Sin K, et al: Determinants of chronic obstructive pulmonary disease in Chinese patients in Hong Kong. Int J Tuberc Lung Dis 2007;11:502-507.
7.
Pasipanodya JG, Miller TL, Vecino M, Munguia G, Garmon R, Bae S, et al: Pulmonary impairment after tuberculosis. Chest 2007;131:1817.
8.
Govender N, Lalloo UG, Naidoo RN: Occupational exposures and chronic obstructive pulmonary disease : a hospital-based case-control study. Thorax 2011;66:597-602.
9.
Vargha G: Fifteen-year follow-up of lung function in obstructive and non-obstructive pulmonary tuberculosis. Acta Med Hung 1983;40:271-276.
10.
Willcox PA, Ferguson AD: Chronic obstructive airways disease following treated pulmonary tuberculosis. Respir Med 1989;83:195-198.
11.
Plit ML, Anderson R, Van Rensburg CEJ, Page-Shipp L, Blott JA, Fresen JL, et al: Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis. Eur Respir J 1998;12:351-356.
12.
Radovic M, Ristic L, Stankovic I, Pejcic T, Rancic M, Ciric Z, et al: Chronic airflow obstruction syndrome due to pulmonary tuberculosis treated with directly observed therapy - serious changes in lung function. Med Arh 2011;65:265-269.
13.
Snider GL, Doctor L, Demas TA, Shae AR: Obstructive airway disease in patients with treated pulmonary tuberculosis. Am Rev Respir Dis 1971;103:625-640.
14.
Ramos LMM, Sulmonett N, Ferreira CS, Henriques JF, DeMiranda SSDE: Functional profile of patients with tuberculosis sequelae in a university hospital*. J Bras Pneumol 2006;32:43-47.
15.
Gothi D, Shah DV, Joshi JM: Clinical profile of diseases causing chronic airflow limitation in a tertiary care centre in India. J Assoc Physicians India 2007;55:551-555.
16.
Chung K-P, Chen J-Y, Lee C-H, Wu H-D, Wang J-Y, Lee L-N, et al: Trends and predictors of changes in pulmonary function after treatment for pulmonary tuberculosis. Clin Sci 2011;66:549-556.
17.
Girdler-Brown BV, White NW, Ehrlich RI, Churchyard GJ: The burden of silicosis, pulmonary tuberculosis and COPD among former Basotho goldminers. Am J Ind Med 2008;51:640-647.
18.
Lam KB, Jiang CQ, Jordan RE, Miller MR, Zhang WS, Cheng KK, et al: Prior TB, smoking, and airflow obstruction : a cross-sectional analysis of the Guangzhou Biobank cohort study. Chest 2010;137:593-600.
19.
Menezes AMB, Hallal PC, Perez-Padilla R, Jardim J, Muino A, Lopez M, et al: Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America. Eur Respir J 2007;30:1180-1185.
20.
Caballero A, Torres-Duque CA, Jaramillo C, Bolivar F, Sanabria F, Osorio P, et al: Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL Study). Chest 2008;133:343-349.
21.
Lamprecht B, Mcburnie MA, Vollmer WM, Welte T, Nizankowska-mogilnicka E, Bateman E, et al: COPD in never smokers : results from the population-based Burden of Obstructive Lung Disease study. Chest 2011;139:752-763.
22.
Idolor LF, de Guia TS, Francisco NA, Roa CC, Ayuyao FG, Tady CZ, et al: Burden of obstructive lung disease in a rural setting in the Philippines. Respirology 2011;16:1111-1118.
23.
Lee SW, Kim YS, Kim D, Oh Y, Lee S: The risk of obstructive lung disease by previous pulmonary tuberculosis in a country with intermediate burden of tuberculosis. J Korean Med Sci 2011;26:268-273.
24.
Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al: International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study. Lancet 2007;370:741-750.
26.
Jithoo A: Respiratory Symptoms and Chronic Obstructive Pulmonary Disease. Prevalence and Risk Factors in a Predominantly Low-Income Urban Area of Cape Town, South Africa; PhD thesis, University of Cape Town, 2006.
27.
Ehrlich RI, Adams S, Baatjies R, Jeebhay MF: Chronic airflow obstruction and respiratory symptoms following tuberculosis: a review of South African studies. Int J Tuberc Lung Dis 2011;15:886-891.
28.
Anno H, Tomashefski JF: Studies on the impairment of respiratory function in pulmonary tuberculosis. Am Rev Tuberc Pulmon Dis 1955;71:333-348.
29.
Kawoos MY, Khanna BK: A study of airway obstruction in pulmonary tuberculosis. Indian J Chest Dis Allied Sci 1979;21:18-23.
30.
Birath G, Caro J, Malmberg R, Simonsson BG: Airways obstruction in pulmonary tuberculosis. Scand J Resp Dis 1966;47:27-36.
31.
Lancaster JF, Tomashefski JF: Tuberculosis - a cause of emphysema. Am Rev Respir Dis 1963;87:435-437.
32.
Gaesnsler EA, Lindgren I: Chronic bronchitis as an etiologic factor in obstructive emphysema; preliminary report. American Rev Res Dis 1959;80:185-193.
33.
Hallett WY, Martin CJ: The diffuse obstructive pulmonary syndrome in a tuberculosis sanatorium. I. Etiologic factors. Ann Intern Med 1961;54:1146-1155.
34.
Martin CJ, Hallett WY: The diffuse obstructive pulmonary syndrome in a tuberculosis sanatorium. II. Incidence and symptoms. Ann Intern Med 1961;54:1156-1164.
35.
Hnizdo E, Singh T, Churchyard G: Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment. Thorax 2000;55:32-38.
36.
Van Zyl Smit RN, Pai M, Yew WW, Leung CC, Zumla A, Bateman ED, et al: Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. Eur Respir J 2010;35:27-33.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.